Presentation of results from open-label extension study of Xenazine announced
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington’s disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p
Read more on News-Medical-Net
Concussions on the rise in college hoops
KANSAS CITY, Mo. — Diving for a loose ball during a summer pickup game, North Carolina center Tyler Zeller knocked heads with another player.
Read more on SportingNews
Originally posted 2010-03-10 21:04:11.




